- Home
- OTLK vs AAME Comparison
OTLK vs AAME Comparison
Compare OTLK & AAME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- AAME
- Stock Information
- Founded
- OTLK 2010
- AAME 1968
- Country
- OTLK United States
- AAME United States
- Employees
- OTLK N/A
- AAME N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- AAME Life Insurance
- Sector
- OTLK Health Care
- AAME Finance
- Exchange
- OTLK Nasdaq
- AAME Nasdaq
- Market Cap
- OTLK 48.3M
- AAME 46.3M
- IPO Year
- OTLK 2016
- AAME N/A
- Fundamental
- Price
- OTLK $2.34
- AAME $3.08
- Analyst Decision
- OTLK Strong Buy
- AAME
- Analyst Count
- OTLK 5
- AAME 0
- Target Price
- OTLK $9.60
- AAME N/A
- AVG Volume (30 Days)
- OTLK 1.1M
- AAME 25.2K
- Earning Date
- OTLK 08-14-2025
- AAME 08-12-2025
- Dividend Yield
- OTLK N/A
- AAME 0.65%
- EPS Growth
- OTLK N/A
- AAME N/A
- EPS
- OTLK N/A
- AAME 0.10
- Revenue
- OTLK $1,505,322.00
- AAME $198,977,000.00
- Revenue This Year
- OTLK N/A
- AAME N/A
- Revenue Next Year
- OTLK $407.74
- AAME N/A
- P/E Ratio
- OTLK N/A
- AAME $29.45
- Revenue Growth
- OTLK N/A
- AAME 6.98
- 52 Week Low
- OTLK $0.87
- AAME $1.25
- 52 Week High
- OTLK $8.32
- AAME $3.37
- Technical
- Relative Strength Index (RSI)
- OTLK 63.83
- AAME 78.68
- Support Level
- OTLK $1.95
- AAME $2.18
- Resistance Level
- OTLK $2.14
- AAME $2.38
- Average True Range (ATR)
- OTLK 0.17
- AAME 0.21
- MACD
- OTLK 0.03
- AAME 0.06
- Stochastic Oscillator
- OTLK 77.62
- AAME 76.09
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About AAME Atlantic American Corporation
Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance.